Lloyds Banking Group

Lloyds Banking renews contract with the AA

The AA will adapt its breakdown app, with bespoke functionality for Lloyds packaged bank account customers, providing them with the ability to report and track their breakdown digitally on their phones or tablets

AA badge
The "breakdown experience", as the AA calls it, is rarely a happy one but the AA hopes to make it more bearable via digital tracking

Roadside recovery outfit AA plc (LON:AA.) has won a five-year contract to supply breakdown services to 2.4mln Lloyds Banking Group PLC (LON:LLOY) customers.

The AA said the contract renewal is one of the largest roadside assistance contracts in the UK and will service around 2.4mln Lloyds Packaged Bank Account (PBA) customers.

READ: AA posts sharp fall in profits after cold weather leads to more call-outs

The AA will continue to support PBA customers with roadside assistance, home start, recovery and accident management services. In addition, and for the first time Lloyds’ PBA customers will be provided with access to a range of digital driving services.

“The recent contract renewals, extensions and wins are a testament to the value our operational scale, service excellence and breadth of innovative customer solutions can bring to our B2B [business-to-business] partners and personal members,” said the appropriately named chief executive officer of the AA, Simon Breakwell.

Shares in AA were up 1.0% at 86.11p in early deals.

Quick facts: Lloyds Banking Group

Price: £0.50

Market: LSE
Market Cap: £35.11 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: Scancell back in the clinic with a phase II trial of its...

Scancell Holdings PLC's (LON:SCLP) Cliff Holloway tells Proactive London's Andrew Scott they've begun the UK arm of the phase II trial of its flagship skin cancer treatment. The trial is testing the safety and efficacy of SCIB1 in metastatic melanoma patients who are also receiving Merck’s...

15 hours, 10 minutes ago


Transaction in Own Shares

11 hours, 1 minute ago

Transaction in Own Shares

3 days, 11 hours ago

Transaction in Own Shares

4 days, 11 hours ago

Transaction in Own Shares

5 days, 11 hours ago

Transaction in Own Shares

6 days, 11 hours ago

Director/PDMR Shareholding

6 days, 14 hours ago

Transaction in Own Shares

1 week, 1 day ago

Transaction in Own Shares

1 week, 4 days ago

2 min read